KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

被引：0
|
作者：
Ascierto, P. A. [1 ]
Ferrucci, P. F. [2 ]
Stephens, R. [3 ]
Del Vecchio, M. [4 ]
Atkinson, V. [5 ]
Schmidt, H. [6 ]
Schachter, J. [7 ]
Queirolo, P. [8 ]
Long, G. V. [9 ]
Di Giacomo, A. M. [10 ]
Svane, I. [11 ]
Lotem, M. [12 ]
Bar-Sela, G. [13 ]
Couture, F. [14 ]
Mookerjee, B. P. [15 ]
Ghori, R. [16 ]
Ibrahim, N. [16 ]
Moreno, B. Homet [16 ]
Ribas, A. [17 ]
机构：
[1] Ist Nazl Tumori Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy
[2] Ist Europeo Oncol, Oncol, Milan, Italy
[3] Auckland City Hosp, Med Oncol, Auckland, New Zealand
[4] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[5] Greenslopes Private Hosp, Gallipoli Med Res Fdn, Med Oncol, Brisbane, Qld, Australia
[6] Aarhus Univ Hosp, Oncol, Aarhus, Denmark
[7] Sheba Med Ctr Tel HaShomer, Ctr Canc, Inst Oncol, Oncol,Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel
[8] IRCCS San Martino IST, Oncol Med, Genoa, Italy
[9] Univ Sydney, Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia
[10] Univ Hosp Siena, Ctr Immunooncol, Med Oncol, Siena, Italy
[11] Univ Copenhagen, Herlev Hosp, Oncol, Herlev, Denmark
[12] Hadassah Hebrew Med Ctr, Sharett Inst Oncol, Med Oncol, Jerusalem, Israel
[13] Rambam Hlth Care Campus, Oncol, Haifa, Israel
[14] Laval Univ, Ctr Hosp Univ Quebec Res Ctr, Hematol, Quebec City, PQ, Canada
[15] Novartis, Oncol Clin Dev, E Hanover, NJ USA
[16] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[17] Ronald Reagan UCLA Med Ctr, Med Oncol, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1244O
引用
收藏
页码：442 / 442
页数：1
相关论文
共 50 条
  • [41] MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)
    Ribas, A.
    Chesney, J.
    Long, G. V.
    Kirkwood, J. M.
    Dummer, R.
    Puzanov, I.
    Hoeller, C.
    Gajewski, T. F.
    Gutzmer, R.
    Rutkowski, P.
    Demidov, L.
    Arenberger, P.
    Shin, S. J.
    Ferrucci, P. F.
    Diede, S. J.
    Anderson, J. R.
    Treichel, S.
    Chan, E.
    Hodi, F. S.
    Gogas, H. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S868 - S869
  • [42] ASCENT-04/KEYNOTE-D19: Phase 3 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in 1L programmed death-ligand 1-positive (PDL1+) metastatic triple-negative breast cancer (mTNBC)
    Huober, J.
    Tolaney, S. M.
    De Azambuja, E.
    Emens, L. A.
    Pan, W.
    Huang, J.
    Sun, S. W.
    Schmid, P.
    SWISS MEDICAL WEEKLY, 2022, 152 : 66S - 67S
  • [43] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) 1 chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes Castan, J.
    Guo, Z.
    Karantza, V.
    Aktan, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D plus trametinib (T) in the phase II BRF113928 study.
    Planchard, David
    Besse, Benjamin
    Kim, Tae Min
    Quoix, Elisabeth A.
    Souquet, Pierre jean
    Mazieres, Julien
    Barlesi, Fabrice
    Groen, Harry J. M.
    Smit, Egbert F.
    Baik, Christina S.
    Cho, Byoung Chul
    Kelly, Ronan Joseph
    Socinski, Mark A.
    Novello, Silvia
    Rigas, James R.
    Giannone, Vanessa
    D'amelio, Anthony Michael
    Zhang, Pingkuan
    Mookerjee, Bijoyesh
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF plus MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D plus T) v ipilimumab/nivolumab (I plus N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.
    Feinberg, Bruce A.
    Kish, Jonathan
    Ghate, Sameer R.
    Ndife, Briana
    Lee, Choo Hyung
    McAllister, Lindsay
    Mehta, Sonam
    Nakasato, Antonio Reis
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
    Qin, Shukui
    Fang, Weijia
    Ren, ZhengGang
    Shuangyan, Ou
    Lim, Ho Yeong
    Zhang, Feng
    Choi, Hye Jin
    Tong, Jiandong
    Tao, Min
    Xu, Aibing
    Cheng, Ashley Chi Kin
    Lu, Chang-Hsien
    Chiu, Chang-Fang
    Wahid, Mohamed Ibrahim A.
    Kamble, Shital
    Norquist, Josephine M.
    Zhong, Wen Yan
    Li, Chen
    Chen, Zhendong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)
    Tolaney, S. M.
    De Azambuja, E.
    Emens, L. A.
    Loi, S.
    Pan, W.
    Huang, J.
    Sun, S. W.
    Lai, C.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S664 - S665
  • [48] Phase II Study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 naive or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases.
    Burton, Elizabeth M.
    Amaria, Rodabe Navroze
    Glitza, Isabella Claudia
    Milton, Denai R.
    Diab, Adi
    Patel, Sapna Pradyuman
    McQuade, Jennifer Leigh
    Honaker, Virginia
    Wong, Michael K. K.
    Hwu, Patrick
    Wargo, Jennifer Ann
    Davies, Michael A.
    Tawbi, Hussein Abdul-Hassan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
    Hubner, R.
    Xu, J.
    Kato, K.
    Raymond, E.
    Shu, Y.
    Pan, Y.
    Jiang, Y.
    Zhang, J.
    Park, S. R.
    Kojima, T.
    Lin, C-Y.
    Gotovkin, E.
    Wyrwicz, L. S.
    Ishihara, R.
    Wu, H.
    Peng, Y.
    Wang, L.
    Li, L.
    Yoon, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S853 - S853
  • [50] Randomized, global, phase 3 study of tislelizumab (TIS) plus chemotherapy (chemo) versus placebo (PBO) plus chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
    Raymond, Eric
    Hubner, Richard
    Gotovkin, Evgeny
    Wyrwicz, Lucjan
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Pazo-Cid, Roberto
    Xu, Jianming
    Kato, Ken
    Tao, Aiyang
    Wang, Lei
    Peng, Yanyan
    Li, Liyun
    Yoon, Harry H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 340 - 340
12345